Please use this identifier to cite or link to this item:
|Title:||Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.|
|Authors:||Rembach, Alan;Watt, Andrew D;Wilson, William J;Villemagne, Victor L;Burnham, Samantha C;Ellis, Kathryn A;Maruff, Paul;Ames, David;Rowe, Christopher C;Macaulay, S Lance;Bush, Ashley I;Martins, Ralph N;Masters, Colin L;Doecke, James D|
|Institutional Author:||AIBL Research Group|
|Affiliation:||The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia.|
CSIRO Mathematics, Informatics & Statistics, North Ryde, NSW, Australia.
CSIRO Preventative Health Flagship: Mathematics, Informatics and Statistics, Perth, WA, Australia.
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia Department of Psychiatry, St. George's Hospital, University of Melbourne, VIC, Australia National Ageing Research Institute, Parkville, VIC, Australia.
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia CogState Ltd., Melbourne, VIC, Australia.
National Ageing Research Institute, Parkville, VIC, Australia.
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia.
CSIRO Molecular and Health Technologies, Preventative Health Flagship, Parkville, VIC, Australia.
Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia.
CSIRO Mathematics, Informatics & Statistics, North Ryde, NSW, Australia CSIRO Molecular and Health Technologies, Preventative Health Flagship, Parkville, VIC, Australia The Australian E-Health Research Centre, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
|Citation:||Journal of Alzheimer's Disease : Jad; 40(1): 95-104|
|Abstract:||We evaluated the utility of longitudinal measures of plasma amyloid-β (Aβ) as a means to identify pre-symptomatic cognitive decline in Alzheimer's disease (AD) when coupled to neuroimaging and neuropsychological parameters.Participants from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study were grouped based upon cognitive change and changes in measurable levels of neocortical amyloid over 36 months. Participants were classified as those who transitioned for cognitive decline and change in neocortical amyloid, those healthy controls that did not transition, and stable AD participants over 36 months.Comparisons of plasma Aβ levels between the transition and non-transitional groups showed Aβ1-42 and the Aβ1-42/Aβ1-40 ratio were significantly decreased at baseline (p = 0.008 and p = 0.002, respectively) and at 18 months (p = 0.003 and p = 0.004, respectively). Both measures of neocortical amyloid and two previously published composite scores validated the creation of the novel transitional grouping (p < 0.0001). In addition Aβn-42 performed well as a longitudinal prognostic indicator of transition toward cognitive decline, with a significant decrease in the transition group at the 18 month time point (p = 0.01).We demonstrated that baseline plasma Aβ1-42 and the Aβ1-42/Aβ1-40 ratio were putative biomarkers indicative of cognitive decline and validated this result using 18 month data. We created a novel transitional grouping and validated this measure using published measures of neocortical amyloid and composite memory scores. These findings suggest that longitudinal plasma Aβ could contribute to a pre-symptomatic biomarker panel for AD.|
|Internal ID Number:||24334723|
Pittsburgh compound B
neocortical amyloid burden
positron emission topography
Aged, 80 and over
Aniline Compounds.diagnostic use
Mental Status Schedule
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.